(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654292

白血球除去療法の市場規模、シェア、動向分析レポート：製品タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年

Leukapheresis Market Size, Share & Trends Analysis Report By Product Type (Leukapheresis Devices, Leukapheresis Disposables), By Application (Research Application, Therapeutic Application), By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
白血球除去療法の市場規模、シェア、動向分析レポート：製品タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月21日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

白血球除去輸血（ロイカフェレシス）の市場規模と動向：

世界の白血球除去輸血（ロイカフェレシス）の市場規模は、2024年に2億1,130万米ドルと推定され、2025年から2030年にかけてCAGR 11.05%で成長すると予測されています。

血液疾患や自己免疫疾患の有病率の増加、白血球除去輸血手順の技術的進歩、個別化医療に対する需要の高まりが市場成長の原動力になると予想されます。さらに、研究開発活動への投資が増加していることも、市場成長にさらに寄与しています。

白血病、リンパ腫のような血液疾患、関節リウマチや多発性硬化症のような自己免疫疾患の罹患率の上昇は、市場の成長を著しく促進しています。例えば、Leukemia &Lymphoma Society（白血病リンパ腫協会）の報告によると、米国では2023年に推定合計184,720人が白血病、リンパ腫、骨髄腫の診断を受けると予想されています。同様に、2023年5月、2,200万人を対象としたLancet誌の研究は、自己免疫疾患が10人に1人の割合で罹患していることを明らかにし、社会経済的、季節的、地域的要因の影響を強調し、関節リウマチ、1型糖尿病、多発性硬化症を含むこれらの疾患の原因に関する洞察を提供しています。したがって、予測期間中、白血球除去輸血の需要を促進します。

白血球除去輸血技術の進歩は、手技の効率、安全性、結果を向上させています。自動化システム、連続フロー遠心分離システム、クローズドシステムデバイスの導入は、白血球除去輸血の精度と有効性を高めると予想されます。それによって手技時間が短縮され、ドナーの不快感が最小限に抑えられ、細胞収集収量が最適化されます。2022年10月、米国アフェレーシス学会（ASFA）の臨床応用委員会は、IEC治療小委員会、AABB、その他様々な組織とともに、ホワイトペーパーを作成しました。この文書は、免疫エフェクター細胞療法の一部である小児および成人患者から単核球を採取する白血球除去輸血を実施するためのガイドラインを、商業的な試みであれ研究イニシアチブであれ概説しています。従って、予測期間中の市場成長を促進すると予想されます。

治療戦略を個々の患者プロファイルに合わせる個別化医療アプローチへのシフトが、白血球除去療法の需要を促進しています。白血球洗浄は、キメラ抗原受容体（CAR）T細胞療法や幹細胞移植などの細胞ベースの治療において重要な役割を果たしています。2023年12月、Transfusion and Apheresis Science誌に掲載された論文では、末梢血からの白血球採取から始まるCAR-T細胞製造の課題が強調されました。この論文は、CAR-T細胞療法を成功させるためには、効果的な白血球採取が重要な役割を果たすことを強調し、T細胞の品質に影響を与える要因を理解することの重要性を強調しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 白血球除去市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 白血球除去市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 白血球除去市場：製品タイプの推定・動向分析

  • セグメントダッシュボード
  • 世界の白血球成分分析市場の製品タイプ変動分析
  • 世界の白血球成分分析市場規模と動向分析、製品タイプ別、2018～2030年
  • 白血球除去装置
    • 遠心分離装置
    • 膜分離装置
  • 白血球除去使い捨て製品

第5章 白血球除去市場：用途の推定・動向分析

  • セグメントダッシュボード
  • 世界の白血球成分分析市場の用途の変動分析
  • 世界の白血球成分分析市場規模と動向分析、用途別、2018～2030年
  • 調査用途
    • がん調査
    • 免疫学調査
    • その他
  • 治療用途
    • 血液疾患
    • I 自己免疫疾患
    • その他

第6章 白血球除去市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 世界の白血球成分分析市場の最終用途変動分析
  • 世界の白血球成分分析市場規模と動向分析、最終用途別、2018～2030年
  • 血液センター
  • 学術調査機関
  • 製薬・バイオテクノロジー企業
  • 病院・クリニック

第7章 白血球除去市場：製品タイプ、用途、最終用途別の地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業市況分析、2024年
  • 企業プロファイル/上場企業
    • Charles River Laboratories International, Inc.
    • Adacyte Therapeutics
    • AllCells, LLC
    • Asahi Kasei Medical
    • Haemonetics Corporation
    • Macopharma
    • Cerus Corporation
    • SB-Kawasumi Laboratories, Inc.
    • StemExpress, LLC.
    • Caltag Medsystems Limited
    • Lonza Group AG
    • ZenBio
    • Terumo BCT, Inc.
    • Macopharma SA
    • Miltenyi Biotec
    • Fresenius SE &Co. KGaA
    • Guangzhou Daji Medical Science
    • MEDICA SpA
    • SB-Kawasumi Laboratories, Inc.
    • PuriBlood Medical Co. Ltd.
    • Beijing ZKSK Technology Co. Ltd.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global leukapheresis market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 4 Global leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America leukapheresis market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 8 North America leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 11 U.S. leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 14 Canada leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 17 Mexico leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe leukapheresis market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 21 Europe leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 24 Germany leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 27 UK leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 30 France leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 31 France leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 33 Italy leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 36 Spain leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 39 Denmark leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 42 Sweden leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 45 Norway leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific leukapheresis market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 52 China leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 53 China leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 55 Japan leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 58 India leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 59 India leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 61 South Korea leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 64 Australia leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 67 Thailand leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America leukapheresis market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 71 Latin America leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 74 Brazil leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 77 Argentina leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA leukapheresis market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 81 MEA leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 84 South Africa leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 90 UAE leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE leukapheresis market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait leukapheresis market, by product type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait leukapheresis market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait leukapheresis market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Leukapheresis market: Market outlook
  • Fig. 5 Leukapheresis market: Segment outlook
  • Fig. 6 Leukapheresis market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Leukapheresis market driver impact
  • Fig. 9 Leukapheresis market restraint impact
  • Fig. 10 Leukapheresis market: Product type outlook and key takeaways
  • Fig. 11 Leukapheresis market: Product type movement analysis
  • Fig. 12 Leukapheresis devices market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Centrifugal devices market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Membrane separators market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Leukapheresis disposables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Leukapheresis market: Application outlook and key takeaways
  • Fig. 17 Leukapheresis market: Application movement analysis
  • Fig. 18 Research application market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Cancer research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Immunology research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Therapeutics application market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 Hematologic disorders market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 24 Autoimmune diseases market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 26 Leukapheresis market: End use outlook and key takeaways
  • Fig. 27 Leukapheresis market: End use movement analysis
  • Fig. 28 Blood centers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Global leukapheresis market: Regional outlook and key takeaways
  • Fig. 33 Global leukapheresis market: Regional movement analysis
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-357-9

Leukapheresis Market Size & Trends:

The global leukapheresis market size was estimated at USD 211.3 million in 2024 and is projected to grow at a CAGR of 11.05% from 2025 to 2030. The increasing prevalence of blood disorders and autoimmune diseases, technological advancements in leukapheresis procedures, and growing demand for personalized medicine are expected to drive the market growth. Moreover, the increasing investments in research and development activities are further contributing to the market growth.

The rising incidence of blood disorders like leukemia, lymphoma, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis are significantly driving the market growth. For instance, the Leukemia & Lymphoma Society reports that an estimated total of 184,720 people in the U.S. are expected to receive a diagnosis of leukemia, lymphoma, or myeloma in 2023. Similarly, in May 2023, a study in The Lancet involving 22 million people found autoimmune disorders affect 1 in 10 individuals, highlighting the influence of socioeconomic, seasonal, and regional factors and offers insights into the causes of these diseases, including Rheumatoid arthritis, Type 1 diabetes, and Multiple sclerosis. Thus, propelling the demand for leukapheresis over the forecast period.

The advancements in leukapheresis technologies are improving the efficiency, safety, and outcomes of the procedure. The introduction of automated systems, continuous flow centrifugation systems, and closed-system devices is expected to enhance the precision and effectiveness of leukapheresis. Thereby reducing the procedure times, minimizing donor discomfort, and optimizing cell collection yields. In October 2022, the Clinical Applications Committee of The American Society for Apheresis (ASFA), along with the IEC Therapy Subcommittee, AABB, and various other organizations, prepared a white paper. This document outlines guidelines for performing leukapheresis to retrieve mononuclear cells from pediatric and adult patients who are part of immune effector cell therapies, whether for commercial endeavors or research initiatives. Thus, anticipated to propel the market growth over the forecast period.

The shift towards personalized medicine approaches that tailor treatment strategies to individual patient profiles is fueling the demand for leukapheresis procedures. Leukapheresis plays a crucial role in cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy and stem cell transplantation. In December 2023, an article in Transfusion and Apheresis Science underscored the challenges in manufacturing CAR-T cells, beginning with the extraction of T cells through leukapheresis from peripheral blood. The article emphasized the critical role of an effective leukapheresis product in achieving successful CAR-T cell therapy and highlighted the significance of comprehending the factors that impact T cell quality.

Global Leukapheresis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global leukapheresis market report based on product type, application, end-use, and region:

  • Product Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Leukapheresis Devices
    • Centrifugal Devices
    • Membrane Separators
  • Leukapheresis Disposables
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Research Application
    • Cancer Research
    • Immunology Research
    • Others
  • Therapeutics Application
    • Hematologic Disorders
    • Autoimmune Diseases
    • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Blood Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Type
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Leukapheresis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The increasing prevalence of blood disorders and autoimmune diseases
      • 3.2.1.2. Technological advancements in leukapheresis procedures
      • 3.2.1.3. Growing demand for personalized medicine
      • 3.2.1.4. Rising investments in research
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High equipment costs
  • 3.3. Leukapheresis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Leukapheresis Market: Product Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Leukapheresis Market Product Type Movement Analysis
  • 4.3. Global Leukapheresis Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 4.4. Leukapheresis Devices
    • 4.4.1. Leukapheresis devices market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Centrifugal Devices
      • 4.4.2.1. Centrifugal Devices market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Membrane Separators
      • 4.4.3.1. Membrane separators market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Leukapheresis Disposables
    • 4.5.1. Leukapheresis disposables market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Leukapheresis Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Leukapheresis Market Application Movement Analysis
  • 5.3. Global Leukapheresis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Research Application
    • 5.4.1. Research application market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Cancer Research
      • 5.4.2.1. Cancer research market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Immunology Research
      • 5.4.3.1. Immunology research market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Therapeutics Application
    • 5.5.1. Therapeutics application market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.5.2. Hematologic Disorders
      • 5.5.2.1. Hematologic disorders market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.5.3. I Autoimmune Diseases
      • 5.5.3.1. Autoimmune diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.5.4. Others
      • 5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Leukapheresis Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Leukapheresis Market End Use Movement Analysis
  • 6.3. Global Leukapheresis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Blood Centers
    • 6.4.1. Blood centers institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Hospitals & Clinics
    • 6.7.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Leukapheresis Market: Regional Estimates & Trend Analysis by Product Type, Application, and End Use

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.9. Denmark
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Regulatory framework
      • 7.5.9.3. Competitive scenario
      • 7.5.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Regulatory framework
      • 7.8.5.3. Competitive scenario
      • 7.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Charles River Laboratories International, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Adacyte Therapeutics
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. AllCells, LLC
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Asahi Kasei Medical
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Haemonetics Corporation
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Macopharma
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Cerus Corporation
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. SB-Kawasumi Laboratories, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. StemExpress, LLC.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Caltag Medsystems Limited
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Lonza Group AG
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. ZenBio
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Terumo BCT, Inc.
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Macopharma SA
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. Miltenyi Biotec
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Product benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. Fresenius SE & Co. KGaA
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Product benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Guangzhou Daji Medical Science
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Product benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. MEDICA S.p.A
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Product benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. SB-Kawasumi Laboratories, Inc.
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Product benchmarking
      • 8.4.19.4. Strategic initiatives
    • 8.4.20. PuriBlood Medical Co. Ltd.
      • 8.4.20.1. Company overview
      • 8.4.20.2. Financial performance
      • 8.4.20.3. Product benchmarking
      • 8.4.20.4. Strategic initiatives
    • 8.4.21. Beijing ZKSK Technology Co. Ltd.
      • 8.4.21.1. Company overview
      • 8.4.21.2. Financial performance
      • 8.4.21.3. Product benchmarking
      • 8.4.21.4. Strategic initiatives